Amendments to the Specification:

Please replace the paragraph beginning on page 8, line 1, with the following amended paragraph:

FIGURE 11 shows the adenoviral construct (SEQ ID NO:381). The TRPM7siRNA-pAdTrack (l) (containing the hairpin (SEQ ID NOS:382 and 383)) under the H1 promoter and GFP under a CMV promoter as well as adeno recombination sequences was cotransfected with pAdEasy (containing viral sequences) into HEK cells and the cells selected with kanamycin. Recombined virus containing the TRPM7 siRNA hairpin and GFP sequences was then be produced from these cells.

Please replace the paragraph beginning on page 8, line 22, with the following amended paragraph:

FIGURE 14 shows the effect of treating the cultures with Tat-9cTRPM7. The sequence of Tat-9cTRPM7 is: [Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Ser-Thr-Asn- Ser-Val-Arg-Leu-Met-Leu] or[YGRKKRRQRRR-STNSVRLML] (SEQ ID NO:258), whereby the first 11 residues correspond to the cell membrane transduction domain of the human immunodeficiency virus type 1 (HIV-1) Tat protein and the last 9 residues correspond to the last 9 amino acids of the C- terminus of human TRPM7 (accession Q96QT4). We predict similar results with a Tat-conjugated peptide encoding the last 9 residues of the mouse TRPM7 C-terminus (YGRKKRRQRRR-ATNSVRLML (SEQ ID NO:380); accessionQ923J1). (A) Neuronal survival at 20h in the indicated concentrations ofTat-9cTRPM7 in the absence of excitotoxic challenge.(B) Neuronal survival 20h after challenging the cultures for lh with the indicated concentration of NMDA. Tat-9cTRPM7 was applied immediately after the NMDA challenge.

Please add the paper copy of the substitute sequence listing attached in the Appendix to the application.